Biomarkers in community-acquired pneumonia: A state-of-the-art review

Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Biomarkers are useful tools for searching for antibiotic therapy modifications and for CAP diagnosis, prognosis and follow-up treatment. This non-systematic state-of-the-art review presents the biologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Seligman, Renato, Ramos-Lima, Luis Francisco, do Amaral Oliveira, Vivian, Sanvicente, Carina, Pacheco, Elyara F., Rosa, Karoline Dalla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488993/
https://www.ncbi.nlm.nih.gov/pubmed/23184211
http://dx.doi.org/10.6061/clinics/2012(11)17
Descripción
Sumario:Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Biomarkers are useful tools for searching for antibiotic therapy modifications and for CAP diagnosis, prognosis and follow-up treatment. This non-systematic state-of-the-art review presents the biological and clinical features of biomarkers in CAP patients, including procalcitonin, C-reactive protein, copeptin, pro-ANP (atrial natriuretic peptide), adrenomedullin, cortisol and D-dimers.

Ejemplares similares